Lipantil Micro

Fenofibrate, the active ingredient in Lipantil Micro, is a fibrate presented as an oral formulation for oral use. It lowers elevated triglyceride levels and is used in adults with certain lipid disorders.

GNH USA supplies Lipantil Micro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fenofibrate acts on the lipid metabolism pathway and is indicated for several dyslipidaemic conditions.

Hypertriglyceridemia: reduces plasma triglyceride concentrations. Mixed dyslipidemia: improves the overall lipid profile by lowering triglycerides and modestly raising HDL‑cholesterol. Primary hypercholesterolemia (adjunct therapy): used together with statins to enhance lipid control when statin therapy alone is insufficient.

Fenofibrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Gastrointestinal discomfort such as nausea, abdominal pain or dyspepsia. - Headache or dizziness. - Muscle pain or weakness. - Elevated liver enzymes. - Skin rash or pruritus. - Increased serum creatinine.

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy, especially when combined with statins. - Acute liver injury or hepatitis. - Pancreatitis. - Severe hypersensitivity reactions including Stevens‑Johnson syndrome. - Renal failure secondary to muscle breakdown. - Unexplained bleeding or severe thrombocytopenia.

When prescribing Fenofibrate, clinicians should consider several safety measures.

Monitor lipid levels: assess treatment efficacy regularly. Monitor liver function: obtain baseline and periodic liver enzyme tests. Assess renal function: adjust use in patients with impaired kidney function. Evaluate muscle symptoms: educate patients to report unexplained muscle pain or weakness. Review concomitant medications: avoid known major interacting drugs. Store at ambient temperature: keep in the original container, protect from moisture and light.

Fenofibrate interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Gemfibrozil: markedly increases risk of myopathy. - Cyclosporine: elevates fenofibrate plasma concentrations. - Strong CYP2C8 inhibitors (e.g., gemfibrozil, clopidogrel): raise exposure and toxicity risk. - HIV protease inhibitors: may increase fenofibrate levels. - Bile‑acid sequestrants (e.g., cholestyramine): reduce oral absorption.

Moderate Interactions (Monitor Closely): - Statins, particularly simvastatin: increased myopathy risk. - Warfarin: potential alteration of INR. - Oral contraceptives: may affect lipid parameters. - Antihypertensives: monitor blood pressure changes. - Thyroid hormone replacement: assess thyroid function tests.